0 results for 'AbbVie'
Opioid Manufacturer Teva Pharmaceuticals Reaches $4.25B Global Settlement
Under the settlement, announced on Tuesday, Teva would provide $3.7 billion to states, local communities and Native American tribes, plus $1.2 billion worth of generic Narcan, a nasal spray used to treat opioid overdoses.Opioid Manufacturer Teva Pharmaceuticals Reaches $4.25B Global Settlement
Teva negotiated the deal with the plaintiffs executive committee in the opioid multidistrict litigation, along with a "working group" of attorneys general of 12 states, including Texas, California, New York and Pennsylvania.Opioid Manufacturer Teva Pharmaceuticals Reaches $4.25B Global Settlement
Teva negotiated the deal with the plaintiffs executive committee in the opioid multidistrict litigation, along with a "working group" of attorneys general of 12 states, including California, New York, Pennsylvania and Texas.The 2022 GC Compensation Survey: New York Legal Chiefs Get a Post-Pandemic Pay Bump
"The market remains very competitive. There are incredible amounts of hiring. Money is being thrown at everyone," said Deborah Ben-Canaan, senior practice leader for in-house counsel recruiting at Major, Lindsey & Africa.The 2022 GC Compensation Survey: Legal Chief Pay Spikes After Pandemic Pause
"The market remains very competitive. There are incredible amounts of hiring. Money is being thrown at everyone," said Deborah Ben-Canaan, senior practice leader for in-house counsel recruiting at Major, Lindsey & Africa.View more book results for the query "AbbVie"
King & Spalding Defends AbbVie, Allergan Over Claims Surgical Scaffold Caused Cancer
This suit was surfaced by Law.com Radar. Read the complaint here.Allergan, Teva Settle Opioid Trial As Closing Arguments Begin in San Francisco
The two drug companies have agreed to pay $54 million to settle San Francisco's opioid trial on Tuesday, but closing arguments continue against a third defendant, Walgreens.Court Dismisses Relator's False Claims Court Dismisses Relator's False Claims
What GCs Should Know About California's Blocked Board Diversity Laws
It's possible, but unlikely, that activist investors and groups could successfully leverage the recent California rulings to go after companies that have diversity policies.